|
WO2014010250A1
(en)
|
2012-07-13 |
2014-01-16 |
Chiralgen, Ltd. |
Asymmetric auxiliary group
|
|
DK2872147T3
(da)
|
2012-07-13 |
2023-02-20 |
Wave Life Sciences Ltd |
Fremgangsmåde til fremstilling af kirale oligonukleotider
|
|
EP3094728B1
(en)
|
2014-01-16 |
2022-03-09 |
Wave Life Sciences Ltd. |
Chiral design
|
|
AU2015367378A1
(en)
|
2014-12-17 |
2017-06-15 |
Proqr Therapeutics Ii B.V. |
Targeted RNA editing
|
|
CN117965536A
(zh)
|
2015-07-22 |
2024-05-03 |
波涛生命科学有限公司 |
寡核苷酸组合物及其方法
|
|
MA46427A
(fr)
|
2015-10-09 |
2018-08-15 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
|
MA43822A
(fr)
|
2016-03-13 |
2018-11-28 |
Wave Life Sciences Ltd |
Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides
|
|
EP3452596A4
(en)
|
2016-05-04 |
2020-03-18 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS
|
|
US11013757B2
(en)
|
2016-06-03 |
2021-05-25 |
Wave Life Sciences Ltd. |
Oligonucleotides, compositions and methods thereof
|
|
EP3475424A1
(en)
|
2016-06-22 |
2019-05-01 |
ProQR Therapeutics II B.V. |
Single-stranded rna-editing oligonucleotides
|
|
WO2018041973A1
(en)
|
2016-09-01 |
2018-03-08 |
Proqr Therapeutics Ii B.V. |
Chemically modified single-stranded rna-editing oligonucleotides
|
|
WO2018098264A1
(en)
|
2016-11-23 |
2018-05-31 |
Wave Life Sciences Ltd. |
Compositions and methods for phosphoramidite and oligonucleotide synthesis
|
|
CN110248665A
(zh)
|
2017-02-06 |
2019-09-17 |
Mpeg La有限责任公司 |
具有降低的肾清除的多聚体寡核苷酸
|
|
US11603532B2
(en)
|
2017-06-02 |
2023-03-14 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
CA3065523A1
(en)
|
2017-06-02 |
2018-12-06 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
WO2018237194A1
(en)
|
2017-06-21 |
2018-12-27 |
Wave Life Sciences Ltd. |
Compounds, compositions and methods for synthesis
|
|
AU2018316159A1
(en)
|
2017-08-08 |
2020-02-06 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|
|
CN111108096A
(zh)
|
2017-09-18 |
2020-05-05 |
波涛生命科学有限公司 |
寡核苷酸制备技术
|
|
EP3694530A4
(en)
|
2017-10-12 |
2021-06-30 |
Wave Life Sciences Ltd. |
COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
|
|
WO2019105414A1
(zh)
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
HRP20250277T1
(hr)
|
2017-12-01 |
2025-05-09 |
Suzhou Ribo Life Science Co., Ltd. |
Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba
|
|
CN110944675B9
(zh)
|
2017-12-01 |
2024-08-09 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CN118291456A
(zh)
|
2017-12-01 |
2024-07-05 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
JP7360716B2
(ja)
|
2017-12-01 |
2023-10-13 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用
|
|
CN110959011B
(zh)
|
2017-12-29 |
2023-03-28 |
苏州瑞博生物技术股份有限公司 |
缀合物及其制备方法和用途
|
|
JP2021521140A
(ja)
|
2018-04-12 |
2021-08-26 |
ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. |
オリゴヌクレオチド組成物及びその使用方法
|
|
CA3098624A1
(en)
|
2018-05-11 |
2019-11-14 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
GB201808146D0
(en)
|
2018-05-18 |
2018-07-11 |
Proqr Therapeutics Ii Bv |
Stereospecific Linkages in RNA Editing Oligonucleotides
|
|
WO2020038377A1
(zh)
|
2018-08-21 |
2020-02-27 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的药物组合物和缀合物及其用途
|
|
JP7376952B2
(ja)
|
2018-09-30 |
2023-11-09 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
siRNA複合体及びその調製方法と使用
|
|
JP7507495B2
(ja)
|
2018-12-28 |
2024-06-28 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
|
|
US20230287406A1
(en)
*
|
2019-03-04 |
2023-09-14 |
Mpeg La, L.L.C. |
Multimeric oligonucleotides with enhanced bioactivity
|
|
AU2020241559A1
(en)
|
2019-03-20 |
2021-11-11 |
Wave Life Sciences Ltd. |
Technologies useful for oligonucleotide preparation
|
|
MX2021012981A
(es)
|
2019-04-25 |
2022-01-18 |
Wave Life Sciences Ltd |
Composiciones de oligonucleotido y metodos de uso de las mismas.
|
|
CN113227376B
(zh)
|
2019-05-22 |
2024-04-09 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
CN113286888B
(zh)
|
2019-05-22 |
2023-12-22 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
JP7610848B2
(ja)
|
2019-05-22 |
2025-01-09 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、薬物組成物及び複合体ならびに調製方法と使用
|
|
CN113795582B
(zh)
|
2019-05-24 |
2024-05-24 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
WO2021026150A1
(en)
*
|
2019-08-05 |
2021-02-11 |
Arrowhead Pharmaceuticals, Inc. |
Methods for the treatment of apoc3-related diseases and disorders
|
|
JP2022546055A
(ja)
*
|
2019-08-29 |
2022-11-02 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
化合物、薬物複合体及びその調製方法と使用
|
|
MX2022009419A
(es)
|
2020-01-31 |
2022-08-25 |
Avilar Therapeutics Inc |
Compuestos de union al asgpr para la degradacion de proteinas extracelulares.
|
|
AU2021225957A1
(en)
*
|
2020-02-28 |
2022-09-08 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating SMN2
|
|
CN115485381A
(zh)
*
|
2020-03-26 |
2022-12-16 |
国立研究开发法人国立循环器病研究中心 |
以apoc3为靶点的反义核酸
|
|
US11478533B2
(en)
|
2020-04-27 |
2022-10-25 |
Novo Nordisk A/S |
Semaglutide for use in medicine
|
|
MX2022014606A
(es)
|
2020-05-22 |
2023-03-08 |
Wave Life Sciences Ltd |
Composiciones de oligonucleótidos bicatenarios y métodos relacionados con las mismas.
|
|
BR112023000279A2
(pt)
*
|
2020-07-09 |
2023-01-31 |
Hoffmann La Roche |
Processo para a produção de um oligonucleotídeo de estrutura p=o/p=s misturado, solução de oxidação e método para avaliar a qualidade de uma solução de oxidação
|
|
CN111978179A
(zh)
*
|
2020-08-27 |
2020-11-24 |
青岛科技大学 |
一种6-羟基己酸酯的合成方法
|
|
AU2022268925A1
(en)
|
2021-05-03 |
2023-11-16 |
Avilar Therapeutics, Inc. |
Potent asgpr-binding compounds for the degradation of immunoglobulins and other proteins
|
|
CN117580953B
(zh)
*
|
2021-07-16 |
2025-07-18 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
IL311500A
(en)
*
|
2021-09-21 |
2024-05-01 |
Wave Life Sciences Ltd |
Double stranded oligonucleotide compositions and methods relating thereto
|
|
WO2023083442A1
(en)
|
2021-11-10 |
2023-05-19 |
Norchem Limited |
Process for producing a triazine ring containing compound, addition product, triazine ring containing polyol, use of the addition product, use of the triazine ring containing polyol and pu/pir foam obtained by using the triazine ring containing polyol
|
|
EP4479535A1
(en)
|
2022-02-14 |
2024-12-25 |
ProQR Therapeutics II B.V. |
Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
|
|
EP4555085A1
(en)
|
2022-07-15 |
2025-05-21 |
ProQR Therapeutics II B.V. |
Chemically modified oligonucleotides for adar-mediated rna editing
|
|
EP4555086A1
(en)
|
2022-07-15 |
2025-05-21 |
ProQR Therapeutics II B.V. |
Oligonucleotides for adar-mediated rna editing and use thereof
|
|
GB202215614D0
(en)
|
2022-10-21 |
2022-12-07 |
Proqr Therapeutics Ii Bv |
Heteroduplex rna editing oligonucleotide complexes
|
|
KR20250113455A
(ko)
|
2022-11-24 |
2025-07-25 |
프로큐알 테라퓨틱스 Ⅱ 비.브이. |
유전성 hfe-혈색소침착증의 치료를 위한 안티센스 올리고뉴클레오티드
|
|
GB202218090D0
(en)
|
2022-12-01 |
2023-01-18 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
|
|
WO2024121373A1
(en)
|
2022-12-09 |
2024-06-13 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of cardiovascular disease
|
|
GB202300865D0
(en)
|
2023-01-20 |
2023-03-08 |
Proqr Therapeutics Ii Bv |
Delivery of oligonucleotides
|
|
WO2024175550A1
(en)
|
2023-02-20 |
2024-08-29 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
|
|
GB202304363D0
(en)
|
2023-03-24 |
2023-05-10 |
Proqr Therapeutics Ii Bv |
Chemically modified antisense oligonucleotides for use in RNA editing
|
|
JP2026510408A
(ja)
|
2023-03-24 |
2026-04-02 |
プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ |
神経障害の処置のためのアンチセンスオリゴヌクレオチド
|
|
EP4688143A1
(en)
|
2023-03-27 |
2026-02-11 |
ProQR Therapeutics II B.V. |
Antisense oligonucleotides for the treatment of liver disease
|
|
WO2024256620A1
(en)
|
2023-06-16 |
2024-12-19 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of neurodegenerative disease
|
|
AU2024287308A1
(en)
|
2023-07-13 |
2025-12-18 |
Korro Bio, Inc. |
Rna-editing oligonucleotides and uses thereof
|
|
EP4774393A1
(en)
|
2023-09-07 |
2026-07-15 |
ProQR Therapeutics II B.V. |
Antisense oligonucleotides for the treatment of metabolic disorders
|
|
AU2024379264A1
(en)
|
2023-11-16 |
2026-05-14 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of classic galactosemia
|
|
WO2025128799A1
(en)
|
2023-12-12 |
2025-06-19 |
Korro Bio, Inc. |
Double-stranded rna-editing oligonucleotides and uses thereof
|
|
AU2024402199A1
(en)
|
2023-12-20 |
2026-07-16 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of huntington's disease
|
|
WO2025199466A1
(en)
|
2024-03-22 |
2025-09-25 |
Purdue Research Foundation |
Liver-specific asialoglycoprotein receptor targeting ligands, conjugates comprising same, and related compositions and methods of use
|
|
GB202404661D0
(en)
|
2024-04-02 |
2024-05-15 |
Proqr Therapeutics Ii Bv |
Antisense oligoncleotides for the treatment of liver disease
|
|
WO2025224230A1
(en)
|
2024-04-25 |
2025-10-30 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of fatty liver disease
|
|
GB202410081D0
(en)
|
2024-07-11 |
2024-08-28 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for the treatment of cardiovascular disease
|
|
WO2026022136A1
(en)
|
2024-07-23 |
2026-01-29 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of metabolic disorders
|
|
WO2026060374A2
(en)
|
2024-09-16 |
2026-03-19 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of neurological disorders
|
|
WO2026068781A1
(en)
|
2024-09-30 |
2026-04-02 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of liver disease
|
|
WO2026093339A1
(en)
|
2024-10-29 |
2026-05-07 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of peroxisome biogenesis disorders in the zellweger spectrum (pbd-zsd)
|
|
WO2026136663A1
(en)
|
2024-12-18 |
2026-06-25 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of neurodegenerative disease
|